Pharmacological differences and switching among anti‐CGRP monoclonal antibodies: A narrative review.

Antibodies targeting either the calcitonin gene–related peptide (CGRP), such as galcanezumab, fremanezumab, and eptinezumab, or the receptor (erenumab) have been approved for the prevention of episodic and chronic migraine. Although widely used and generally effective, a proportion of patients disco...

Descripción completa

Detalles Bibliográficos

Publicado en:	Headache: The Journal of Head & Face Pain Vol. 65; no. 2; pp. 342 - 353
Autores principales:	Romozzi, Marina, Munafò, Antonio, Burgalassi, Andrea, De Cesaris, Francesco, Vigani, Giulia, Altamura, Claudia, Rivi, Veronica, Guerzoni, Simona, Calabresi, Paolo, Raffaelli, Bianca, Iannone, Luigi Francesco
Formato:	review tables/charts Journal Article
Publicado:	Wiley-Blackwell Feb2025
Acceso en línea:	Ver este registro en EBSCOhost